News
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
EQS-Adhoc: Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
EQS-Adhoc: Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
EQS-Adhoc: Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
EQS-Adhoc: Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
EQS-Adhoc: Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
EQS-Adhoc: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
EQS-Adhoc: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
DGAP-Adhoc: BB Biotech AG closes the 2021 fiscal year with a loss
DGAP-Adhoc: BB Biotech AG closes the 2021 fiscal year with a loss
DGAP-Adhoc: BB Biotech AG mit Verlust im Geschäftsjahr 2021
DGAP-Adhoc: BB Biotech AG mit Verlust im Geschäftsjahr 2021
DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed
DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed
DGAP-News: BB BIOTECH AG: 2021 war ein schwieriges Jahr für die Biotechaktienmärkte - Erhöhung der Dividende auf CHF 3.85 vorgeschlagen
DGAP-News: BB BIOTECH AG: 2021 war ein schwieriges Jahr für die Biotechaktienmärkte - Erhöhung der Dividende auf CHF 3.85 vorgeschlagen
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
EQS-Adhoc: Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
EQS-Adhoc: Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
EQS-Adhoc: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
EQS-Adhoc: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
EQS-Adhoc: Relief Comments on Lawsuit Filed Against It by NeuroRx
EQS-Adhoc: Relief Comments on Lawsuit Filed Against It by NeuroRx
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth
EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth